Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-FR Version v1-EN
Language French English
Date Updated 2024-03-08 2024-02-02
Drug Identification Number 02491060 02491060
Brand name EMGALITY EMGALITY
Common or Proper name galcanezumab injection galcanezumab injection
Company Name ELI LILLY CANADA INC ELI LILLY CANADA INC
Ingredients GALCANEZUMAB GALCANEZUMAB
Strength(s) 120MG 120MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS
Packaging size Carton package containing one 120 mg/mL single-use prefilled syringe Carton package containing one 120 mg/mL single-use prefilled syringe
ATC code N02CD N02CD
ATC description
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date
Actual start date 2024-02-02 2024-02-02
Estimated end date 2024-03-08 2024-03-01
Actual end date 2024-03-07
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments The estimated end date represents projected availability at the main Lilly warehouse. For any questions or concerns, please contact our Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays). The estimated end date represents projected availability at the main Lilly warehouse. For any questions or concerns, please contact our Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays).
Health Canada comments